Search

Displaying results 4041 - 4050 of 4359 in total
  1. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101 is being evaluated as a therapeutic drug when injected into this deep brain structure that is known to function abnormally in Parkinson’s patients.

  2. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.

  3. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  4. Drug

    Sulfaguanidine

    go.drugbank.com/drugs/DB13726
    Experimental

    Sulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.

  5. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...

  6. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  7. Drug

    Resatorvid

    go.drugbank.com/drugs/DB05943
    Investigational

    Resatorvid is an investigational compound designed for the treatment of severe sepsis.

  8. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  9. Drug

    Afimetoran

    go.drugbank.com/drugs/DB16580
    Investigational

    Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioac...

  10. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].